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Objective: To evaluate the effects of moderate weight loss, in overweight patients with angina, on plasma coagulation,
fibrinolytic indicies and pain frequency.
Design: Single-stranded 12-week dietary intervention, an individualised eating plan with quantitative advice delivered by a
dietitian. Target weight loss of 0.5 kg per week.
Setting: Outpatient research clinic.
Subjects: Fifty-four volunteers with angina pectoris were recruited. Five subjects withdrew, so 27 males, 22 females, mean body
mass index (BMI) 29.3 (s.d. 4.3) kg=m2 and age 60.3 (s.d. 6.5) y completed the intervention.
Measurements: Body weight and frequency of anginal pain. Plasma fibrinogen, red cell aggregation (RCA), viscosity, factor VII
activity, plasminogen activator inhibitor (PAI) activity, tissue plasminogen activator antigen (t-PA), plasma cholesterol,
triglyceride and insulin.
Results: After the 12-week dietary intervention period, mean body weight fell by 3.5 (s.d. 2.6) kg or 4.3% (P¼ 0.0001), range
711.7 to þ1.7 kg. Mean angina frequency fell by 1.8 (s.d. 3.6) from 3.2 to 1.4 episodes=week (P¼0.009) and plasma
cholesterol by 0.4 (s.d. 0.7) from 6.3 to 5.9 mmol=l (P¼0.0001). HDL cholesterol and triglyceride were unchanged. Of the
coagulation and fibrinolytic factors, factor VII activity and RCA were significantly reduced by 5 (s.d. 20), IU=dl (P¼0.04) and 1.3
(s.d. 1.3) arbitrary units (P¼0.014), respectively.
Conclusions: A conventional dietetic intervention, resulting in 4% weight loss, offers the potential to reduce atherosclerotic and
thrombotic risk, and to reduce pain frequency, in angina patients. Given the importance of this result in a public health context,
these results indicate that this may be a fruitful area for future nutrition research.
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Introduction
Relatively modest weight loss is increasingly recognised to
have major health benefits for overweight people (Goldstein,
1992). Weight gain leads to a wide range of disabling symp-
toms, as well as being an important coronary risk factor
(Hubert et al, 1983; Higgins et al, 1988). Being overweight
favours the development of diabetes (Chan et al, 1994),
which can be controlled with sufficient weight loss (UK
PDS. 1995). Other risk factors that are elevated by overweight
include hypertension (Ramsey et al, 1978), blood lipids and
coagulation factors (Williamson et al, 1995; Heinrich et al,
1993). All improve with loss of 5 – 10% or 5 – 10 kg body
weight (Goldstein, 1992). Life expectancy is increased with
intentional weight loss in overweight people who have
obesity-related complications, particularly diabetes (Lean
et al, 1990; Williamson et al, 1995,1999).
As well as promoting a more atherogenic blood lipid
profile, overweight promotes coronary heart disease by ele-
vating plasma coagulation factor VII activity, fibrinogen,
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measures of blood rheology and impaired fibrinolysis (Le
Devehat et al, 1992; Meade et al, 1986). All these changes are
associated with increased coronary risk via thrombogenesis
(Heinrich et al, 1993; Lowe & Forbes, 1981). Increased visc-
eral fat is particularly associated with impaired fibrinolytic
activity (raised levels of plasminogen activator inhibitor, PAI;
Kockx et al, 1999). Tissue plasminogen activator antigen (t-
PA) and PAI activity, factor VII activity and fibrinogen all
show greater elevations in those with known coronary dis-
ease and angina (Aznar et al, 1988).
Bahadori et al, (1996) have reported that close to 40% of
obese angina patients do not have significant coronary artery
disease, and so a clinical benefit from weight loss could be
expected without necessarily modifying atheroma. Some
previous studies have shown that weight reduction improves
established measurements of coagulation, rheology and fibri-
nolysis (Poggi et al, 1994; Palareti et al, 1994). Most studies
used short-term very low calorie diet (VLCD) regimens in
otherwise healthy subject groups, where effects from acute,
severe energy restriction are likely to confound any effects of
weight loss per se. The amount of weight loss in these trials
(18% body weight) is more than is achievable in routine
practice (Poggi et al, 1994; Palareti et al, 1994).
The aims of the present study were to investigate the
effects of moderate weight loss on both established biochem-
ical and haematological risk factors for cardiovascular dis-
ease, and on the frequency of chest pain in overweight
angina patients already on treatment for coronary heart
disease. The dietary advice concerned dietary composition




A single-stranded study design was employed with paired
analysis (before and after the intervention) within subjects.
Patients and methods
Patients actively seeking weight management were recruited
by local advertising. All patients had received a previous
medical diagnosis of angina pectoris, which was determined
from Rose questionnaires (Rose, 1963). An ultrasonic flow
detector was used to investigate the presence of peripheral
vascular disease (Yao et al, 1969). Each patient was requested
to attend the Department of Human Nutrition on five occa-
sions over the 12-week intervention period. Body weight,
height, waist and hip circumferences were measured and
body mass index (BMI) was calculated (WHO, 1987). Skin-
fold thicknesses were measured (Lean et al, 1996) and used to
estimate body fat as a percentage of body weight. The same
observer carried out all measurements without reference to
previous measurements. At baseline and after 12 weeks the
frequency of anginal pain and use of glyceryl trinitrate
(GTN) were recorded alongside food and drink consumption
in a 7-day diary.
Dietary intervention
In order to ensure an appropriate dietary prescription to
achieve a standard energy deficit in each subject, given
that predicted energy requirement figures are those for
healthy people, individual dietary prescriptions were based
on resting energy expenditure, estimated from indirect
calorimetry (Deltatrac). No patients engaged regularly in
physical exercise, so an activity factor of 1.3resting
energy expenditure was used to estimate total daily require-
ments (COMA, 1991) and a daily energy deficit of 2510 kJ
(600 kcal) was applied (Lean & James, 1986). Advised dietary
composition was in line with current national dietary guide-
lines (COMA, 1991); greater than 50% of energy derived
from carbohydrate, less than 35% from fat and under 20%
from protein. Patients were asked to prospectively record
their food intakes using 7 day weighed diaries at baseline and
at week 12.
Plasma measures
Fasting blood was sampled from the anticubital vein with
minimal stasis between 9 and 11 am following a 5 min
supine rest. Measurements were made pre- and post-dietary
intervention. Triglycerides and total cholesterol were mea-
sured on an automated analysis system (Boehringer Man-
nheim, Lewes, Sussex, UK) and high density lipoprotein
cholesterol (HDL) was measured using b-quantification and
ultracentrifugation. Whole blood and plasma-viscosity were
measured at high shear rates (over 300 s71) at 37C in a
Harkness viscometer (Lowe et al, 1993). Haematocrit was
measured with a Hawksley microcentrifuge, RCA was
assessed photometrically in a cone-plate aggregometer (Myr-
enne GmbH, Roetgan, Germany).
Fibrinogen was measured using an automated thrombin-
clotting assay (Clauss, 1957). Factor VII activity was mea-
sured using a one-stage clotting assay and rabbit thrombo-
plastin and results were recorded as a percentage of a
reference plasma pool (Lowe et al, 1997). The total plasma
concentrations of t-PA antigen were determined by an ELISA
(Tintelize t-PA, Biopool, Sweden). The intra- and inter-assay
coefficient of variation were 8.9 and 9.0%, respectively. The
plasminogen activator inhibitor activity (PAI-1) was mea-
sured using a chromogenic microtitre assay (COAtestPAI,
Chromogenix) with an intra-assay coefficient of variation
of 7.9% and an inter-assay variation of 8.1%.
Statistical and sample size considerations
The sample size of 45 patients was chosen to provide an 80%
power to detect a clinically important difference equal in size
to the population standard deviation for factor VII activity,
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red cell aggregation and t-PA antigen as principle outcome
measures using a 5% significance test (Woodward, 1999).
The data were approximately normally distributed, from
inspection of distribution plots. Before and after means were
compared using paired Student’s t-tests. Pearson’s correlation
coefficient was applied to investigate the relationships
between changes in body weight and secondary outcome
measurements. Ethical approval for the study design was
obtained from the Glasgow Royal Infirmary Joint Ethics
Committee and signed informed consent was secured from
all patients.
Results
Clinical characteristics of study subjects
Fifty-four patients enrolled in the study, of these five with-
drew and 49 overweight, but weight-stable, angina patients
(27 male, 22 post-menopausal females) with a BMI
25 kg=m2 completed the study. The mean age was 60.3 y
(range 41.0 – 67.5). The prescribed medications for these
subjects relevant to their cardiovascular disease were glyceryl
trinitrate spray (27), aspirin (20), diuretic (12), b blocking
agents (29) and lipid-lowering medications (one). There was
no change in any prescribed medications during the study.
There were 11 smokers, seven of whom were male. There was
no reported change in smoking status during the study.
Eleven subjects (two females) showed signs of occlusive
peripheral vascular disease with an ankle branchial pressure
index (ABPI) below 0.9. Mean ABPI was 0.9 (s.d. 0.2). There
was no effect of lowered ABPI measurement on baseline
measures or on changes in biochemical measures.
Energy requirements and dietary intake data
Mean daily energy prescription for all patients was 6217 (s.d.
1498; range 4184 – 1172) kJ; for males, 6941 (s.d. 1292; range
5020 – 10460) kJ and for females, 5322 (s.d. 1292; range
4184 – 7949) kJ. At baseline, median energy intake and
inter quartile range was 7928 (6564 – 8865) kJ, which fell to
6108 (5213 – 8075) kJ (P<0.00001) at week 12. Baseline
median dietary fat intake was 33.4 (29.5 – 38.2)%, which
fell to 30.0 (25.9 – 33.5)% post-intervention.
Weight and body composition
The mean BMI of males was 30.9 (s.d. 4.5) kg=m2 (range
25.6 – 40.9), which was greater (P¼0.04) than that of females
27.8 (s.d. 2.5) kg=m2 (range 25.0 – 32.7). For all patients mean
BMI was 29.3 (s.d. 4.3) kg=m2 (range 25.0 – 40.9). Mean
weight reduction over the 12-week study was 3.5 (2.6) kg,
(P¼0.009, Table 1), close to 60% of the expected loss (Lean &
James, 1986). The frequency of anginal pain between base-
line and week 12 was significantly reduced in all participants
(Table 1, Figure 1).
Thrombogenic factors
At baseline, mean factor VII activity was higher in females
than males, 130 (s.d. 20) vs 114 (s.d. 26) IU=dl (P¼0.04), but
no sex difference was observed in the other measures.
Amongst the haemostatic and fibrinolytic indices measured,
significant reductions between baseline and week 12 were
detected for RCA and factor VII activity (Table 2). There was
some evidence for a reduction in PAI activity in males
(P¼0.09).
Atherogenic factors
Plasma total cholesterol was reduced in all patients
(P¼0.0001), in males (P¼0.0019) and females (P¼0.011),
separately, although HDL cholesterol and triglyceride were
unchanged.
During the course of the study no significant (P<0.05)
correlations were found between changes in body weight, or
alterations in waist circumference, and changes in angina
frequency (Figure 2) or in biochemical measures.
Discussion
The results from this study support the view that modest
weight loss can improve clinical and biochemical indices of
Table 1 Mean (s.d.) of cardiovascular risk factors, fasting plasma biochemistry pre- and post-intervention (n¼49)
Baseline Week 12 Change 95% CI P-value
Weight (kg) 81.6 (11.7) 78.1 (11.3) 73.5 (2.6) 74.2, 72.6 0.0001
BMI (kg=m
2
) 29.3 (4.3) 28.1 (4.0) 71.2 (0.9) 71.5, 70.9 0.0001
Body fat (%) 31.9 (4.8) 31.1 (5.0) 70.8 (1.7) 71.2, 70.3 0.0022
Waist circumference (cm) 103.9 (9.3) 101.6 (10.2) 72.3 (4.5) 73.5, 71.1 0.0005
Waist-to-hip ratio 1.00 (0.06) 0.99 (0.07) 70.01 (0.06) 70.02, þ 0.01 0.40
Plasma insulin (mU=l) 13.1 (8.1) 11.8 (8.9) 71.3 (7.8) 73.7, þ 1.1 0.29
Total cholesterol (mmol=l) 6.3 (1.1) 5.9 (1.0) 70.4 (0.7) 70.6, 70.2 0.0001
HDL cholesterol (mmol=l) 1.3 (0.3) 1.2 (0.3) 70.1 (0.6) 70.1, þ 0.1 0.092
Triglyceride (mmol=l) 1.8 (0.8) 1.7 (1.0) 70.1 (0.6) 70.3, þ 0.1 0.31
Systolic blood pressure (mmHg) 144 (16) 142 (17) 72 (17) 718.5, þ 5.4 0.99
Diastolic blood pressure (mmHg) 86 (10) 85 (18) 71 (19) 719.5, þ 6.5 0.14
Angina frequency (incidents=week) 3.2 (4.5) 1.4 (2.5) 71.8 (3.6) 72.5, 70.9 0.009
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CVD risk and, importantly, that there are clinical benefits in
terms of symptom reduction for overweight patients with
angina. The data cannot, however, be considered definitive
because of the range of weight changes, which places severe
limits on the power of a study of routine management. A
randomised controlled intervention design is the gold stan-
dard for testing causality, provided that a fixed treatment is
used, and that a placebo or some other control treatment is
feasible (Woodward, 1999). As the present study illustrates,
in dietary intervention studies the treatment (weight loss) is
not fixed. As in any study of this kind, the treatment group
includes a wide range of weight changes (in this case from
þ1.7 to 711.7 kg over 12 weeks), which will introduce a
wide variability in secondary consequences such as biochem-
ical or clinical outcomes. Furthermore, an untreated control
group may be problematic, as in practice medically compro-
mised patients seeking weight management are rightly reluc-
Figure 1 Angina frequency before and after intervention. * P<0.05, ** P<0.01 when compared to baseline. Data presented of mean (s.e.m.).
Table 2 Mean (s.d.) coagulation and fibrinolytic measures, pre and post-intervention (n¼49)
Measure Baseline Week 12 Change 95% CI P-value
PAI-1 (% pool) 134 (75) 123 (59) 711 (57) 730.5, þ 5.73 0.10
t-PA antigen (mg=ml) 10.9 (3.2) 10.6 (3.6) 70.3 (2.8) 71.0, þ 0.6 0.21
Fibrinogen (g=l) 3.4 (1.0) 3.6 (0.8) þ 0.2 (0.1) 70.1, þ 0.3 0.15
Factor VII activity (IU=dl) 120 (14) 115 (20) 75 (20) 711.3, þ 0.8 0.04
Haematocrit (%) 45 (0.1) 40 (0.1) 70.5 (0.1) 72.1, þ 1.3 0.32
Red cell aggregation (arbitrary units) 3.9 (1.5) 2.6 (0.6) 71.3 (0.6) 72.3, 70.4 0.014
Plasma viscosity (mPa s) 1.30 (0.08) 1.29 (0.08) 70.01 (0.08) 70.03, þ 0.02 0.33
Figure 2 Relationship between the change in body weight and anginal
frequency.
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tant to ignore their problem and remain in a control group.
Untreated observation ‘non-weight loss’ control groups
usually have a large overlap of weight changes. This has
been shown by participants who had volunteered for a
weight loss study, but were randomised to be held in a 12
week control period prior to commencing the intervention,
whose range of weight changes was 74.9 to þ5.3 kg (Leslie
et al, 2000). Thus the study design chosen, a correlation
analysis between weight change and outcome measures, was
a pragmatic choice (Lean, 2000). If a clinical trial design were
deemed feasible, post-hoc analyses from the current study
could be carried out to derive appropriate samples sizes. If a
controlled intervention study were deemed feasible, post hoc
analyses from the current study could be carried out to
derive appropriate sample sizes. For instance, assuming a
control group with no average change, results from Table 2
suggest that a sample size of 422 in each group would be
expected to be required in order to be 80% sure of detecting a
significant difference in PAI-1 (Woodward, 1999).
The mean 3.5 kg (4%) weight loss after dietary interven-
tion during this 12 week study is similar to that achievable
by a range of approaches in a variety of patient groups. In a
patient group considered as being largely physically inactive,
and in whom weight gain frequently occurs, it represents
considerable success (Goldstein, 1992). It has been shown
that angina can be reduced by other lifestyle interventions
(Barnard et al, 1983), but clinical programmes such as cardiac
rehabilitation have usually concentrated only on exercise,
relaxation and education, without effective dietary or weight
management strategies (ASPIRE Steering Group, 1996). The
present finding of reduced anginal pain frequency is in
accordance with the frequent clinical impression of an
immediate benefit from weight loss in those suffering
angina.
The finding that only some patients showed any benefit
from weight loss suggests that angina patients are a hetero-
geneous group in terms of the relationship between weight
and angina (Figure 2). When patients were recruited, they
were not selected for their reported angina frequency, and
hence there was a wide range in the frequency of anginal
pain (0 – 70 incidents per week) in the study group. However,
as subjects were identified for participation on the basis of
having angina, some reduction in frequency could have
been attributable to secular factors or ‘regression to the
mean’. A possible mechanism by which this clinical observa-
tion could be explained may involve the effect of weight loss
in changing indices of endothelial function. This has been
illustrated in type 2 diabetes mellitus patients, also suffering
from angina pectoris, who when treated with thiazolidine-
dione show a reduction in the frequency of angina pain
(Murakami et al, 1999).
In addition to recording the frequency of anginal pain,
the participants in the present study were asked to record
their frequency of GTN use. However, the majority declined
to do this, and hence their record of anginal frequency
provides the most objective measure possible within the
confines of this study of free living subjects.
In addition to benefits in anginal episodes, we also
observed significant decreases in a number of biochemical
measures, known to be CVD risk factors: total cholesterol,
factor VII activity and RCA. Reduced plasma cholesterol is an
expected benefit of weight loss (Dattilo & Kris-Etherton,
1992). The fact that HDL cholesterol and triglyceride were
unaltered is probably because most patients were on lipid-
lowering drugs and additional weight loss was insufficient to
affect any changes. Additionally, weight loss was completed
at 12 weeks and insufficient time was available for weight
stability to encourage a rise in HDL (Heinrich et al, 1993).
The significant decrease in factor VII activity achieved in the
present study supports the findings of other studies where
both moderate weight loss (Rissanen et al, 2001,Folsom et al,
1993) and much greater weight loss (18%) have been
achieved (Palareti et al, 1994).
In contrast, Baron et al (1989), using a 1200 kcal weight-
reducing diet in overweight subjects, failed to demonstrate a
significant change in factor VII activity with a similar weight
loss. The fall in factor VII activity achieved by Baron et al was
below that observed in similar work carried out in healthy
overweight subjects: mean BMI 34.9 kg=m2 (Hankey et al,
1995). The mean baseline factor VII activity was 5% lower
than that of the angina patients in the present study.
Red cell aggregation (RCA) is a risk factor for cardiovas-
cular disease (Gillum et al, 1995; Bottiger & Carlson, 1980)
and is raised in obesity. The improvement in RCA after
weight loss concurs with similar results in healthy adults
using a VLCD (Palareti et al, 1994) or in type 2 diabetics
(MacRury et al, 1992). The stability of plasma viscosity
following modest weight loss is also in accord with previous
studies (Fanari et al, 1993). Very substantial weight loss is
required to change this measure. A VLCD, with an enormous
daily energy deficit is necessary to reduce plasma viscosity in
those with raised baseline values compared to the present
study (Fanari et al, 1993). Studies which showed falls in
fibrinogen or haematocrit have shown greater weight loss
(>15 kg), than in the present investigation (Palareti et al,
1994; Poggi et al, 1994; Le Devehat et al, 1992). Thus, the
failure of a 4% weight loss to affect plasma fibrinogen in this
study, implies only a small effect of dietary intervention and
weight loss on plasma fibrinogen concentrations (Palareti
et al, 1994; Poggi et al, 1994; Le Devehat et al, 1992; Baron et
al, 1989; Lowe et al, 1992; Broadhurst et al, 1990).
A number of studies have succeeded in lowering PAI
activity and t-PA antigen, following large weight losses in
subjects whose fibrinolytic activity was impaired (Landin
et al, 1990; Palareti et al, 1994; Fehily et al, 1982). The PAI
activity at baseline for our angina patients was 31% below
the values of those ‘simple obese’ subjects in a previous study
(Hankey et al, 1997a,b). The stability of fibrinolytic variables
noted here might be due to the unaltered fibrinolytic sys-
tems of the subjects, and an insufficient weight loss to
change it. Two studies (Rissanen et al, 2001; Folsom et al,
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1993) have demonstrated that moderate weight change is
associated improvements in PAI-1 and factor VII activity. In
addition, Rissanen et al (2001) showed the benefits were still
present with long-term maintenance of weight loss.
In conclusion, a weight management programme for
overweight patients with angina improves symptoms and
some rheological and fibrinolytic and lipid risk factors. These
effects of weight may have been masked, or to some degree
minimised by drug therapy. Routinely administered advice
for weight loss in overweight patients with angina may have
important implications for clinical practice by improving
patient care and quality of life (Lewin et al, 1995). These
outcomes merit further study.
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